Assessing factors that predict cognitive changes in relapsing-remitting multiple sclerosis
Multiparametric Clinical, Radiological, Neuropsychological, and Neurophysiological Assessment to Investigate Prognostic Factors for Disease Evolution and Treatment Response in MS: a Prospective Study.
NA · University Hospital of Mont-Godinne · NCT05510817
This study is trying to find out what factors can help predict changes in thinking and disease progression for people with relapsing-remitting multiple sclerosis who are starting a new treatment.
Quick facts
| Phase | NA |
|---|---|
| Study type | Interventional |
| Enrollment | 50 (estimated) |
| Ages | 18 Years to 50 Years |
| Sex | All |
| Sponsor | University Hospital of Mont-Godinne (other) |
| Locations | 1 site (Yvoir, Namur) |
| Trial ID | NCT05510817 on ClinicalTrials.gov |
What this trial studies
This prospective study aims to identify predictive factors for disease evolution and cognitive status changes in patients with relapsing-remitting multiple sclerosis (RRMS). It employs a multiparametric assessment that includes neuropsychological tests, advanced MRI techniques, patient-reported outcomes, and neurophysiological evaluations. By including 50 patients initiating a new disease-modifying treatment, the study will track cognitive performance and disease progression over time. The goal is to provide neurologists with reliable tools to predict treatment responses and cognitive outcomes.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18-50 with active RRMS who are starting a new disease-modifying therapy.
Not a fit: Patients with progressive forms of multiple sclerosis will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved predictive tools for managing cognitive decline in patients with RRMS.
How similar studies have performed: Other studies have shown promise in using multiparametric assessments for cognitive evaluation in MS, but this specific approach is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * active MS, according to the Lublin criteria * disease duration \< 10 years before initiating or changing a disease-modifying therapies, * relapse- and steroid-free for at least 1 month before MRI acquisition * between 18-50 years old * having given informed consent * with no significant comorbidity other than MS or substance abuse that could interfere with cognitive performances Exclusion Criteria: * progressive forms of MS
Where this trial is running
Yvoir, Namur
- CHU UCL Namur site Godinne — Yvoir, Namur, Belgium (RECRUITING)
Study contacts
- Principal investigator: Frédéric London, MD — University Hospital Mont-Godinne
- Study coordinator: Frédéric London, MD
- Email: frederic.london@chuuclnamur.uclouvain.be
- Phone: +3282413345
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Multiple Sclerosis, Relapsing-Remitting, MRI, evoked potentials, cognitive function, PROMs